Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Thorac Med ; 16(1): 118-125, 2021.
Article in English | MEDLINE | ID: mdl-33680132

ABSTRACT

PURPOSE: This study aims to investigate whether there is a significant difference between typical and atypical parenchymal patterns in the development of fibrosis, which is the most crucial factor affecting morbidity in pulmonary sarcoidosis. METHODS: In our hospital, 145 cases with Siltzbach Types 2 and 3 sarcoidoses diagnosed by clinical, radiological, and histopathologic were retrospectively investigated. Perilymphatic nodules, accompanying mosaic attenuation, and interlobular septal thickening and central peribronchovascular bunch-like thickening on high-resolution computed tomography were assessed as typical. Solid nodules, galaxy finding, consolidation, ground-glass opacity, isolated mosaic attenuation, and interlobular septal thickening, and pleural fluid were accepted as atypical findings. Findings indicating fibrosis were fine and rough reticular opacity, traction bronchiectasis, volume loss, and cystic changes. For the analysis of variables, SPSS 25.0 program was used. RESULTS: Ten (16%) of the 61 cases with typical findings and 16 (19%) of the 84 with atypical findings developed fibrosis (P = 0.827). The mean age of cases with fibrosis was higher. With the cut-off of 50 years, sensitivity was 61.5%, and specificity was 68.9%. The highest fibrosis rate was in cases with ground glass pattern (n = 7/17), whereas higher reversibility rates were in those with miliary pattern (n = 9/12) and galaxy sign (n = 5/6). CONCLUSION: The incidence of fibrosis is higher in the atypical group with no significant difference. The incidence of fibrosis differs in each atypical pattern, being highest in ground-glass opacity and lowest in the miliary pattern.

2.
Turk Thorac J ; 21(5): 350-353, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33031728

ABSTRACT

Hughes-Stovin syndrome (HSS) is a rare disease characterized by deep vein thrombosis and pulmonary and/or bronchial artery aneurysms. A 28-year-old female patient was followed-up for 5 months with pulmonary embolism. When she presented with hemoptysis at her 5th month, pulmonary artery aneurysm was detected on thoracic CT angiography. The abdominal magnetic resonance (MR) angiography revealed thrombus in the inferior vena cava. Because she didin't carry the criteria for Behcet's disease, she was diagnosed as Hughes-Stovin Syndrome (HSS) and steroid treatment was started. The patient who had a response to the treatment, stay in remission for a long time. The prognosis was poor in patients with HSS, and aneurysmal rupture was the main cause of death. In order to emphasize the fact that, when the pulmonary arterial aneurysm is seen, in view of the possibility of Behçet or its variant HSS,rapid onset of treatment can be life-saving. A rare female case is presented in the light of the literature.

3.
Biomark Med ; 13(3): 197-204, 2019 02.
Article in English | MEDLINE | ID: mdl-30604642

ABSTRACT

AIM: We aimed to evaluate platelet-to-lymphocyte ratio (PLR) in patients with sarcoidosis. METHODS: A total of 310 sarcoidosis patients and 220 healthy controls retrospectively were recorded in this study. RESULTS: PLR was significantly higher in patients with sarcoidosis than in the control group, and was also significantly higher in patients with pulmonary involvement in stage 2-3-4 than in stage 1. PLR were significantly positive correlated with erythrocyte sedimentation rate. The cut-off values for PLR for predicting a sarcoidosis diagnosis were determined as 158. CONCLUSION: Increase in PLR value can be used for guiding both the diagnosis of sarcoidosis and the involvement of parenchyma.


Subject(s)
Biomarkers/blood , Blood Platelets/pathology , Lymphocytes/pathology , Sarcoidosis/blood , Sarcoidosis/diagnosis , Adult , Blood Sedimentation , Case-Control Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis , ROC Curve , Retrospective Studies
4.
Respir Care ; 60(2): 239-43, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25316894

ABSTRACT

BACKGROUND: Exacerbations of COPD are a major component of the socioeconomic burden related to COPD, and frequent exacerbations are associated with greater decline in health status. Tracheobronchial infections are involved in 50-70% of exacerbations, so influenza and pneumococcal vaccines are recommended for prevention. The aim of this study was to determine the level of knowledge among COPD patients about the vaccines, find the rate of patients inoculated with both influenza and pneumococcal vaccines, and assess the effectiveness of vaccination status. METHODS: Patients with COPD were recruited from the out-patient clinic of our hospital between September and October 2012. Subject demographic data such as age, gender, level of education, and smoking status were recorded. Vaccination status, number of subjects who were informed by a health-care professional about immunization, and COPD-related emergency or hospital admissions triggered by tracheobronchial infections over 1 y after administration of both influenza and pneumococcal vaccines were noted. RESULTS: Eighty-eight subjects were enrolled during the study period. Eighty-two subjects were male (93.2%), 6 subjects were female (6.8%), and the median age was 61.5 y. According to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006 classification, 5 subjects were in stage 1 (5.7%), 22 subjects were in stage 2 (25%), 34 subjects were in stage 3 (38.6%), and 27 subjects were in stage 4 (30.7%). Sixty-two subjects had graduated from primary school (70.5%), 21 subjects had graduated from high school (23.9%), one subject had graduated from university (1.1%), and 4 subjects had no education (4.5%). Forty-five subjects (51%) were vaccinated. There was no significant correlation between level of education and vaccination status (P=.37). Both COPD-related emergency department and hospital visits were significantly decreased in vaccinated patients with COPD (P<.001 and P=.02, respectively). Of all the subjects, 39.7% (35 of 88 subjects) mentioned that no health-care professional recommended vaccination. CONCLUSIONS: Physicians should be more aware of vaccination and recommend both influenza and pneumococcal vaccines to all patients with COPD to reduce exacerbations.


Subject(s)
Health Knowledge, Attitudes, Practice , Influenza, Human/prevention & control , Pneumonia, Pneumococcal/prevention & control , Pulmonary Disease, Chronic Obstructive/complications , Vaccination/statistics & numerical data , Aged , Educational Status , Emergency Service, Hospital/statistics & numerical data , Female , Hospitalization/statistics & numerical data , Humans , Influenza, Human/complications , Male , Middle Aged , Patient Education as Topic/statistics & numerical data , Pneumonia, Pneumococcal/complications , Pulmonary Disease, Chronic Obstructive/classification , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...